Jefferies Financial Group Boosts Cogent Biosciences (NASDAQ:COGT) Price Target to $28.00

Cogent Biosciences (NASDAQ:COGT - Free Report) had its price objective lifted by Jefferies Financial Group from $23.00 to $28.00 in a research report report published on Monday,Benzinga reports. Jefferies Financial Group currently has a buy rating on the technology company's stock.

Several other research analysts have also weighed in on COGT. HC Wainwright lowered their price objective on Cogent Biosciences from $14.00 to $12.00 and set a "buy" rating for the company in a research report on Tuesday, May 20th. Leerink Partners lifted their price objective on Cogent Biosciences from $16.00 to $18.00 and gave the stock an "outperform" rating in a research report on Monday. Robert W. Baird lowered their price objective on Cogent Biosciences from $8.00 to $7.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Needham & Company LLC reissued a "hold" rating on shares of Cogent Biosciences in a research report on Tuesday, June 17th. Finally, JPMorgan Chase & Co. lifted their price objective on Cogent Biosciences from $21.00 to $25.00 and gave the stock an "overweight" rating in a research report on Thursday, May 29th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $16.33.

Cogent Biosciences Trading Up 23.4%

NASDAQ:COGT traded up $1.77 during trading hours on Monday, hitting $9.35. 31,647,423 shares of the company were exchanged, compared to its average volume of 1,469,509. The stock has a market capitalization of $1.06 billion, a price-to-earnings ratio of -5.08 and a beta of 1.88. Cogent Biosciences has a one year low of $3.72 and a one year high of $12.61. The company has a fifty day simple moving average of $6.13 and a 200 day simple moving average of $6.75.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last announced its earnings results on Tuesday, May 6th. The technology company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.04. Equities research analysts predict that Cogent Biosciences will post -2.42 earnings per share for the current fiscal year.

Institutional Trading of Cogent Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in COGT. Proficio Capital Partners LLC acquired a new position in Cogent Biosciences during the 4th quarter valued at about $93,000. Charles Schwab Investment Management Inc. boosted its stake in Cogent Biosciences by 0.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 833,155 shares of the technology company's stock valued at $6,499,000 after purchasing an additional 7,362 shares during the last quarter. E Fund Management Co. Ltd. acquired a new position in Cogent Biosciences during the 4th quarter valued at about $89,000. Intech Investment Management LLC boosted its stake in Cogent Biosciences by 99.3% during the 4th quarter. Intech Investment Management LLC now owns 56,657 shares of the technology company's stock valued at $442,000 after purchasing an additional 28,233 shares during the last quarter. Finally, Teacher Retirement System of Texas boosted its stake in Cogent Biosciences by 15.4% during the 4th quarter. Teacher Retirement System of Texas now owns 17,983 shares of the technology company's stock valued at $140,000 after purchasing an additional 2,396 shares during the last quarter.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.